TrimRx's Blog

Semaglutide shows metabolic benefits that may slow aging markers — but it’s not a longevity drug. Here’s what the evidence actually supports.

Semaglutide reduces cardiovascular mortality by 20% and slows biological aging markers, but lifespan extension requires sustained metabolic correction

Semaglutide shows neuroprotective effects through GLP-1 receptor activation in the brain, reducing inflammation and potentially improving cognitive

Semaglutide doesn’t treat addiction, but may reduce cravings in recovery by modulating dopamine pathways. Here’s what the research shows and doesn’t.

Semaglutide shows emerging neuroprotective effects in Parkinson’s research. Early trials suggest GLP-1 receptor activity may slow motor symptom

Semaglutide shows 40-70% reduction in Alzheimer’s risk across multiple trials. Mechanisms, dosing, and what patients need to know about GLP-1

Semaglutide smoking cessation shows emerging evidence for reducing nicotine cravings through GLP-1 receptor mechanisms affecting dopamine reward pathways

Semaglutide 2 year results show 10–15% sustained weight loss in clinical trials. Long-term data reveals maintenance patterns, side effects, and metabolic

Semaglutide reduces lean mass 25–40% of total weight loss, compromising power-to-weight ratios and recovery. Athletes need structured protocols.